Australian based biopharmaceutical company Asteri Pharma Pty Ltd (ASTERI Pharma) is proud to partner with ESTEVE, an international specialty pharmaceutical company headquartered in Spain, to provide continued access to a biologic product for children and adolescents aged 2 to 18 with severe primary insulin-like growth factor 1 deficiency (SPIGFD).   ASTERI Pharma’s partnership with ESTEVE highlights its focus on growth in rare disease treatment and meeting unmet patient needs

Australian based biopharmaceutical company ASTERI Pharma Pty Ltd, (ASTERI) is proud to partner with ITALFARMACO, a private multinational group headquartered in Milan, Italy, to continue to commercialise an oral suspension therapy to treat Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND) 1  in Australia and New Zealand. Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease of motor neurons in the brain and spinal

A lack of knowledge about movement disorders compounds the challenges faced by patients with its rarest forms. Support #MoveDisorder Day.

If you’re working in the CNS or sleep disorder space and looking to navigate the Australian market better, Asteri are committed to your caus

With a #strongerPBS, we all benefit together - patients, clinicians, politicians, and industry, by having access to new treatments earlier.

Do we need to look at the protocols for rare diseases differently? There’s too great a cost to our society if we continue the way we are.

A new report assess the effect of long-run changes in the drugs provided by the PBS on mortality and hospital utilisation in Australia.

The Asteri team had the pleasure of joining over 1,500 delegates in attending the ARCS 2023 conference last week.

Asteri catches up with exciting partners and reviews cutting-edge research at AAN's annual conference this week.

Pharma in Focus celebrates new CEO's commitment to Australia market

Rare Disease Company Coalition releases data regarding needs and opportunities within the rare disease community.